Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR8392898

— · cohortSQ2

83df657a-60d5-5aeb-a7d3-b8fccc66218e

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSQ2
subtype
cohortSQ2

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • HEDGEHOG_SIGNALING+0.440
  • E2F_TARGETS+0.420
  • MYC_TARGETS_V1+0.410
  • MTORC1_SIGNALING+0.400
  • G2M_CHECKPOINT+0.380
  • UNFOLDED_PROTEIN_RESPONSE+0.380
  • PROTEIN_SECRETION+0.330
  • MYC_TARGETS_V2+0.300
  • WNT_BETA_CATENIN_SIGNALING+0.300
  • DNA_REPAIR+0.290

Top 10 suppressed

  • ANGIOGENESIS-0.410
  • ALLOGRAFT_REJECTION-0.360
  • KRAS_SIGNALING_UP-0.350
  • COAGULATION-0.310
  • INFLAMMATORY_RESPONSE-0.260
  • INTERFERON_ALPHA_RESPONSE-0.250
  • TNFA_SIGNALING_VIA_NFKB-0.240
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.230
  • COMPLEMENT-0.210
  • NOTCH_SIGNALING-0.210

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-18-5595-01A-01R-1635-07
lung-landscapes@6
—cohortSQ20.889
2TCGA-60-2722-01A-01R-0851-07
lung-landscapes@6
—cohortSQ20.863
3TCGA-66-2792-01A-01R-0980-07
lung-landscapes@6
—cohortSQ20.849
4TCGA-70-6723-01A-11R-1820-07
lung-landscapes@6
—cohortSQ20.847
5TCGA-22-5477-01A-01R-1635-07
lung-landscapes@6
—cohortSQ20.841
6TCGA-68-7755-01A-11R-2125-07
lung-landscapes@6
—cohortSQ20.834
7TCGA-NK-A5CR-01A-11R-A26W-07
lung-landscapes@6
—cohortSQ20.833
8SRR9879288
lung-landscapes@6
—cohortSQ20.832
9TCGA-98-A538-01A-11R-A262-07
lung-landscapes@6
—cohortSQ10.831
10TCGA-33-4538-01A-01R-1201-07
lung-landscapes@6
—cohortSQ20.829

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
HEDGEHOG_SIGNALING0.440Inavolisib— uncovered
E2F_TARGETS0.420Inavolisib— uncovered
MYC_TARGETS_V10.410Inavolisib— uncovered
MTORC1_SIGNALING0.400Inavolisib— uncovered
G2M_CHECKPOINT0.380Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.380Idelalisib— uncovered
PROTEIN_SECRETION0.330Remibrutinib— uncovered
MYC_TARGETS_V20.300Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.300Inavolisib— uncovered
DNA_REPAIR0.290Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.290Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.260Remibrutinib— uncovered
HEME_METABOLISM0.240Temsirolimus— uncovered
GLYCOLYSIS0.230Inavolisib— uncovered
MITOTIC_SPINDLE0.220Inavolisib— uncovered
UV_RESPONSE_UP0.210Idelalisib— uncovered
HYPOXIA0.150Idelalisib— uncovered
ANDROGEN_RESPONSE0.140Inavolisib— uncovered
APICAL_SURFACE0.130Temsirolimus— uncovered
ESTROGEN_RESPONSE_EARLY0.120Inavolisib— uncovered